Kornimate/medical-research-clean huggingface dataset:
prevention of malaria with dihydroartemisinine + piperaquine for forest rangers

Conditions: Malaria

Summary: the purpose of the study is to assess if the antimalarial drugs dihydroartemisinine + piperaquine (dp) are effective in preventing malaria infection for forest ranger

to assess the protective effect of 3-day dp regimen for forest rangers working for long-term in forest where malaria transmission is intense, all eligible forest rangers will be treated with a full course of dp + primaquine to eradicate all parasites which may survive in their blood while staying in non- malaria transmission areas. just before returning back to the forest participants will be randomized to receive either arterakine (dihydroartemisinine (dha)/piperaquine) (intervention arm) or placebo (control arm). participants will be assessed for parasitemia before and after the forest trip with high volume, ultrasensitive, pcr (hvuqpcr). the minimum time span between two forest trips should be 20 days so participants could complete the 14 day primaquine course and the arterakine (dihydroartemisinine (dha)/piperaquine). there is no limit in the duration between trips. participants are tested for p.falciparum, p.vivax infection before they return to the forest. each participant will be visited 2 weeks or later after returning home from the forest and examined. the rationale for the added two weeks is to detect blood stages of infections, which may have been inoculated towards the end of the forest visit. if found to be sick, the patient will be treated according to government treatment guidelines. a 4ml venous blood sample will be obtained for hb and hvusqpcr.

Eligibility criteria:
inclusion criteria: 1. informed consent 2. male, over or equal to18 years of age 3. able and willing to comply with the study requirements and follow-up exclusion criteria: 1. inability to tolerate oral treatment 2. previous episode of haemolysis or severe haemoglobinuria following primaquine 3. glucose-6-phosphate dehydrogenase (g6pd) deficient with hb \< 9 g/dl \* 4. known hypersensitivity or allergy to any study drugs \* if the participant with g6pd deficient gets malaria, primaquine would be used as recommended by world health organization (who) (once a week for 8 weeks) in combination with 3 days of chloroquine.

Keywords: forest ranger p.falciparum p.vivax dihydroartemisinine-piperaquine (dp) primaquine
effect of sacchachitin on healing of a chronic wound

Conditions: Wounds

Summary: sacchachitin gel, prepared from the waste residue of the fruiting body of ganoderma tsugae, was used in a previous study to enhance skin wound healing in animal models. in the present study, the effects of the gel on the activity of matrix metalloproteinases (mmps) and vascular endothelial growth factor (vegf) as well as on the healing of skin wounds in humans are estimated by a clinical trial. the hypothesis regarding the poor healing of the wound is the over-expression of mmp and the inhibition of the angiogenic factors. from the previous animal study, the effect of sacchachitin was to inhibit the activity of mmp and stimulation of vegf and we try to prove the effect over the human wounds from this clinical trial. patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study. the exudates from the wound are collected and analyzed for the activity and concentration of vegf and mmp. the change of the healing process is recorded. positive results are expected from the clinical trial and the patients will get another choice for the treatment of the chronic wound other than skin grafting.

sacchachitin gel, prepared from the waste residue of the fruiting body of ganoderma tsugae, was used in a previous study to enhance skin wound healing in animal models. in the present study, the effects of the gel on the activity of matrix metalloproteinases (mmps) and vascular endothelial growth factor (vegf) as well as on the healing of skin wounds in humans are estimated by a clinical trial. the hypothesis regarding the poor healing of the wound is the over-expression of mmp and the inhibition of the angiogenic factors. from the previous animal study, the effect of sacchachitin was to inhibit the activity of mmp and stimulation of vegf and we try to prove the effect over the human wounds from this clinical trial. patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study. the exudates from the wound are collected and analyzed for the activity and concentration of vegf and mmp. the change of the healing process is recorded. positive results are expected from the clinical trial and the patients will get another choice for the treatment of the chronic wound other than skin grafting.

Eligibility criteria:
inclusion criteria: * patients with a poorly healed wound, in which skin graft is clinically indicated exclusion criteria: * skin infection * vital signs unstable

Keywords: chronic ulcer poor healing the patients with a poorly healed wound, in which skin graft is clinically indicated, are included in this study
accuimr predicts microvascular obstruction and infarct size in stemi patients

Conditions: Coronary Artery Disease; STEMI - ST Elevation Myocardial Infarction; Microvascular Coronary Artery Disease

Summary: in this study, we aimed to investigate the clinical significance of the angiography-based imr calculation method (accuimr) and its prognostic assessment capability by evaluating the concordance or discordance between accuimr values and cardiac magnetic resonance (cmr) results.


Eligibility criteria:
inclusion criteria: * (1) stemi patients who underwent pci within 12 hours of symptom onset. * (2) coronary microvascular function was assessed using contrast-enhanced cmr after pci. exclusion criteria: * (1) suboptimal coronary angiographic images, including inadequate contrast opacification, unsatisfactory projection view, and severe overlap or distortion of the target vessel. * (2) lacking two angiographic projections separated by at least 25° apart post-pci. * (3) inadequate cmr image quality

Keywords: accuimr, cmr, infarct size
bone loss in patients with anorexia nervosa

Conditions: Patients With Anorexia Nervosa

Summary: nutritional deprivation of adolescent girls with anorexia nervosa (an) reduces the bone mass acquisition. a better understanding of this process would improve the medical treatment of bone alteration and its long-term consequences. 160 patients (age \< 38 yr) with an and 160 age-matched controls (con) will be enrolled in this study. the areal bone mineral density (abmd) will be determined using dual-x-ray absorptiometry. calciotropic hormones, bone turnover markers will be concomitantly evaluated.


Eligibility criteria:
inclusion criteria: * informed consent * health insurance regimen or benefit from an health insurance regimen * aged from 14 to 38 years old * women * no pregnant specific inclusion criteria for patient: patient suffering from anorexia nervosa defined by criteria of diagnostic and statistical manual of mental disorders (dsm-iv) specific inclusion criteria for controls: * normal menstrual cycles, * no lifetime history of eating disorders, * bmi between 18 and 25 kg/m² exclusion criteria: * use of treatments may be modify bone mass (bisphosphonates,...) * disease or treatment may be induce osteoporosis * in exclusion period in relation with another study * law protected subject

Keywords: anorexia nervosa bone mineral density teenagers or young women bone remodelling markers
improving neuroprotective strategy for ischemic stroke with poor recanalization after thrombectomy by intra-arterial tnk (insist-tnk)

Conditions: Ischemic Stroke

Summary: in 2015, five randomized trials showed efficacy of endovascular thrombectomy over standard medical care in patients with acute ischemic stroke caused by occlusion of arteries of the proximal anterior circulation. however, sufficient recanalization (mtici2b-3) can 't be acquired in all patients under thrombectomy. there is a lack of evidence that whether salvage intra-arterial thrombolysis is beneficial for patients with insufficient recanalization after endovascular thrombectomy. the extend-ia tnk study indicated that tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. this study intends to explore the proportion of sufficient recanalization (2b/3) after intra-arterial tenecteplase administration in patients undergoing thrombectomy with insufficient recanalization (1/2a).


Eligibility criteria:
inclusion criteria: 1. age ≥18 years; 2. patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy; 3. insufficient perfusion (mtici 1/2a) after endovascular treatment; 4. the availability of informed consent. exclusion criteria: 1. sufficient recanalization (tici 2b-3); 2. more than 3 times of thrombectomy device passes 3. hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage 4. coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia ( \<100000/mm3) 5. severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis 6. severe uncontrolled hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg) 7. patients allergic to any ingredient of drugs in our study 8. unsuitable for this clinical studies assessed by researcher
rogaland trauma system study

Conditions: Trauma

Summary: the purpose of this study is to improve performance, stavanger university hospital (suh) reorganized key system structures and introduced in 2009 mandatory documentation of field revised trauma score on trauma patients, tiered trauma team activation and new guidelines for field triage. through a before and after study, the investigators aim to measure how the quality improvement initiative will influence structure, process and outcomes variables.


Eligibility criteria:
inclusion criteria: * included in trauma registry exclusion criteria: * excluded from trauma registry

Keywords: triage precision
quality of life after laparoscopic removal of essure®

Conditions: Contraceptive Device; Complications; Quality of Life

Summary: a lot of patients seem to complain after hysteroscopic tubal occlusion by essure® device with a worce quality of life. investigators' hypothesis is that essure® laparoscopic removal may improve quality of life. this prospectice study aim to assess the quality of life 1, 3, 6 and 12 months after essure® removal.


Eligibility criteria:
inclusion criteria: * women aged 18 years or more * patients with essure® sterilization device * surgical removal of essure® with bilateral salpingectomy by laparoscopy exclusion criteria: * interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. * impaired lower-limb range of motion preventing positioning for surgery * inability to understand information provided * prisoner or under administrative supervision.
malignancies in transplanted patients

Conditions: Neoplasms

Summary: the aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.


Eligibility criteria:
inclusion criteria: * patients willing and capable of giving written informed consent of participation in the project * patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma) exclusion criteria: * patients with a primary liver cancer as cause of the transplantation

Keywords: immunosuppression
understanding and restoring dopaminergic function in fibromyalgia patients

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a very prevalent and debilitating chronic pain disorder that is difficult to treat. mindfulness-based techniques are regarded as a very promising approach for the treatment of chronic pain and in particular fm. the mindfulness-oriented recovery enhancement (more) intervention, a mindfulness-based group intervention, has shown beneficial effects in opioid-treated chronic pain patients, including reduced pain severity, functional interference, and opioid dosing, by restoring neurophysiological and behavioral responses to reward. first evidence for a hypodopaminergic state and impaired reward processing in fm have been reported. however, little is known about its impact on dopamine (da) function and in particular with regard to da responses to monetary reward in fm. the aim of the present study protocol is to evaluate if more is able to restore the da function in fm patients, in particular with regard to the da responses to reward, and to reduce pain and mood complaints in fm.

the present study is a multi-center randomized controlled trial (rct) with 3 time points: before the intervention, after completion of the intervention and 3-months after completion of the intervention. eighty fm patients will be randomly assigned to either the more intervention (n=40) or to a wait-list control group (n=40). additionally a comparison group of healthy women (n=20) will be enrolled. the more intervention consists of eight 2-hour long group sessions administered weekly over a period of 8 weeks. before and after the intervention, fm participants will undergo \[18f\] dopa positron emission tomography (pet) and functional magnetic resonance (mr) imaging while performing a monetary reward task. the primary outcome will be endogeneous da changes measured with \[18f\] dopa pet at baseline, after the intervention (after 8 weeks for control group), and at 3 months' follow-up. secondary outcomes will be (1) clinical pain measures and fm symptoms using standardized clinical scales 2) functional brain changes 3) measures of negative and positive affect, stress and reward experience in daily life using the experience sampling method (esm) 4) biological measures of stress including cortisol and alpha-amylase. design: if the findings of this study confirm the effectiveness of more in restoring da function, reducing pain and improving mood symptoms, more can be judged to be a promising means to improve quality of life in fm patients. the findings of this trial may inform health care providers about the potential use of the more intervention as a possible non-pharmacological intervention for fm.

Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome * no psychiatric disorders * right handed * older than 18 years, exclusion criteria: * male sex * history of neurological disorders * left handed * psychiatric disorders * current substance or tobacco abuse * current and past substance dependence * schizophrenia spectrum disorder * any other form of chronic pain apart from fibromyalgia

Keywords: dopamine reward f-dopa mindfulness
hysterectomy and levonorgestrel releasing intrauterine system (lng-ius) in the treatment of menorrhagia

Conditions: Menorrhagia

Summary: a randomised study including 236 women referred for essential menorrhagia to five university hospitals in finland was conducted to compare the cost-effectiveness and the quality of life issues in the treatment of menorrhagia.participants were randomly assigned to treatment with lng-ius (n=119), or hysterectomy (n=117), and were monitored for ten years. the primary outcome measures were health related quality of life (hrqol), other measures of psychosocial well-being (anxiety, depression, sexual functioning), and costs.

a randomized vuokko trial was conducted between 1994-2008 to study hysterectomy and lng-ius in the treatment of menorrhagia.overall, 236 women aged 35 to 49 years who were menstruating, had completed their family size, and were eligible for both treatments were randomized to either receive a lng-ius (n=119) or undergo hysterectomy (n=117). the follow-up visits took place six months and 12 months after the treatment, and again five and ten years after the randomization. the primary outcome measures were health related quality of life (hrqol), other measures of psychosocial well-being (anxiety, depression, sexual functioning), and costs. the amount of menstrual blood loss was objectively measured before treatment and after one and five years. the one year the results were published in 2001 (lancet 2001;357:273) and the five year results in 2004 (jama 2004; 291:1456).

Eligibility criteria:
inclusion criteria: * heavy menstrual bleeding * 35-49 years * were menstruating * had completed their family size * were eligible for both treatments exclusion criteria: * submucous fibroids * endometrial polyps * ovarian tumours or cysts, * cervical pathology * urinary and bowel symptoms or pain due to large fibroids * lack of indication for hysterectomy * history of malignancies * menopause * severe depression * metrorrhagia as a main complaint * previous treatment failure with lng-ius * severe acne * uterine malformation

Keywords: randomized controlled trial menorrhagia lng-ius hysterectomy
an extension study to evaluate safety and tolerability of ranibizumab in macular edema secondary to retinal vein occlusion (cohort 2)

Conditions: Macular Edema; Retinal Vein Occlusion

Summary: this is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. the first cohort (reported separately under fvf3426g, nct00379795) enrolled subjects with primary or recurrent choroidal neovascularization (cnv) secondary to age-related macular degeneration (amd) who completed the treatment phase of a genentech sponsored study (fvf2598g (nct00056836), fvf2587g (nct00061594), or fvf2428g (nct00056823)). the second cohort (reported here) enrolled subjects with macular edema secondary to retinal vein occlusion (rvo) who completed the 6-month treatment and 6-month observation phases (12 months total) of a genentech sponsored study (fvf4165g (nct00486018) or fvf4166g (nct00485836)). patients were enrolled within 14 days of completion of the previous study.


Eligibility criteria:
inclusion criteria: * signed informed consent form * the 6-month treatment and 6-month observation phases (12 months total) of a genentech-sponsored ranibizumab study for rvo (fvf4165g or fvf4166g) * expectation by the investigator that the subject may potentially benefit from intravitreal anti-vascular endothelial growth factor (vegf) treatment exclusion criteria: * history of intraocular surgery (including cataract extraction, scleral buckle, etc.) within 1 month prior to day 0 of this extension study * concurrent use of systemic anti-vegf agents * use of rvo treatments not approved by the food and drug administration (fda) in the study eye * use of intravitreal bevacizumab in the study eye and/or fellow eye * macular edema in the study eye due to other causes than rvo such as diabetes * history of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye * history of idiopathic or autoimmune-associated uveitis in either eye * uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 30 mmhg despite treatment with antiglaucoma medication) * pregnancy or lactation * premenopausal women not using adequate contraception * history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications * current treatment for active systemic infection * inability to comply with study or follow-up procedures

Keywords: cnv lucentis amd age-related macular degeneration rvo macular edema secondary to retinal vein occlusion
feasibility of home-based preoperative exercise in older people

Conditions: Colorectal Cancer

Summary: the purpose of the study is to evaluate the feasibility of recruitment procedure, intervention including compliance and the collaboration between in- and out patient clinics of preoperative home-based exercise in older people before colorectal surgery.

the feasibility study will be conducted in order to evaluate the study design of a future rct. feasibility data will eg. consist of study flow description, number of eligible participants, included participants, patients and instructors satisfaction with the intervention, training compliance, reasons for drop-outs, and adverse events. patients waiting for colorectal surgery will be recruited and included after informed consent. physical and respiratory function will be assessed at the hospital before the intervention, the day before surgery and the day before discharge. data on postoperative complications, length of stay and mortality will be collected during the hospital stay. at baseline and six months after surgery, the participants will receive three questionnaires about level of independence in daily living, physical activity and health related quality of life. the intervention will be performed in the older person's home and consists of a combination of high-intensity respiratory training and individually adjusted functional exercise. both groups will receive physical activity advice and malnutrition will be screened to optimize their nutritional status.

Eligibility criteria:
inclusion criteria: * age above 70, understand and speaks the swedish language. surgery due to cancer exclusion criteria: * health status that contradicts participation in the study such as unstable heart disease or severe orthopaedic conditions that prohibits training and severe systematic illness.